retatrutide 20mg dosage — 20mg/vial Reference Standard Triple G 20 mg (Retatrutyd)

Cardiovascular Health, Sleep Apnea, and More Retatrutide is also being evaluated in the TRIUMP Trial Program for potential benefits in cardiovascular health, obstructive sleep apnea, fatty liver disease, chronic kidney disease, and even pain associated with osteoarthritis

Most cases in the trials were mild and resolved without stopping the medication, but its not something to ignore, particularly if its affecting sleep or daily life

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Because retatrutide is not yet licensed in the UK, it is not routinely available for prescribing outside a clinical trial or a specific MHRA access scheme (such as the Early Access to Medicines Scheme [EAMS] or named-patient unlicensed supply)